Michelle C. Miller - Concepedia

Author

Michelle C. Miller

Also Known As

D'Cruz, David, M Miller, M. C Miller, M. Miller, Makenna R. Miller, Michelle C Miller, Michelle C. Miller, Michelle Miller, Michelle C. Miller

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

University of Minnesota Ludwig-Maximilians-Universität München Novartis (United States)Novartis (Switzerland)Institut de Cancérologie de l'Ouest

About

Michelle C. Miller is an author at University of Minnesota specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	17	1.6K
2	Natural Sciences	8	8	185
3	Biochemistry	8	8	226
4	Engineering	2	2	63
5	Health Sciences	2	2	1.1K

Michelle C. Miller

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, New England Journal of Medicine	2016	1.9K
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 Dennis J. Slamon, Patrick Neven, Stephen Chia, Journal of Clinical Oncology Advanced Breast CancerFulvestrant V PlaceboBreast OncologyHealth SciencesMedicine	2018	1.1K
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 Fabrice André, Eva Ciruelos, Dejan Juric, Annals of Oncology	2020	557
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer Luigi Formisano, Yao Lu, Alberto Servetto, Nature Communications	2019	383
Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open‐label clinical trial Deborah Friedman, Carolina Llanos, Peter Izmirly, Arthritis & Rheumatism	2010	237
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer Hope S. Rugo, Fabrice André, Toshinari Yamashita, Annals of Oncology	2020	175
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study Giuseppe Curigliano, P. Gómez Pardo, Funda Meric‐Bernstam, The Breast	2016	132
Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding Ruud P.M. Dings, Michelle C. Miller, Irina V. Nesmelova, Journal of Medicinal Chemistry ImmunologyCancer BiologyTumor BiologyAngiogenesisTargets Human Galectin-1	2012	130
Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus Ellen M. Ginzler, Luiz Sergio Guedes Barbosa, David D’Cruz, Arthritis & Rheumatology	2021	92
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial Gabe S. Sonke, Lowell L. Hart, Mario Campone, Breast Cancer Research and Treatment	2017	91

Page 1